Latest News - Pfizer
Top Corporates Hub
Pfizer
Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?
07.10.2026 13:30
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying the stock right now.
When Dividends Cost More Than Earnings: 6 Stocks in Danger
07.10.2026 11:15
Some of the most recognizable dividend stocks in the market have been paying shareholders with money they do not actually earn, and the accounting trail reveals exactly how far six of them have pushed that math.
Vaxcyte Stock Spikes 35% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
05.10.2026 15:09
Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.
Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That “Sets a New Benchmark”
05.10.2026 14:43
Key TakeawaysVaxcyte shares are up about 36% after its VAX-31 pneumococcal vaccine met every primary goal in OPUS-1, its pivotal adult Phase 3 trial. VAX-31 cleared a stricter-than-usual bar against Pfizer’s Prevnar 20 on all 20 shared strains, but on only 17 of 19 against Merck’s Capvaxive.
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
05.10.2026 14:39
Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes.
Vaxcyte shares surge on late-stage vaccine trial success
05.10.2026 14:32
Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete...
Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
05.10.2026 13:52
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
05.10.2026 13:37
Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.
Vaxcyte Stock Hits New 52-Week High - Here’s Why
05.10.2026 12:55
Vaxcyte Inc. (NASDAQ:PCVX) stock is surging on Monday on positive topline results from its pivotal Phase 3 OPUS-1 trial evaluating VAX-31, an investigational 31-valent pneumococcal conjugate vaccine.The trial assessed the safety, tolerability, and immunogenicity of the candidate in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia.These trial findings will form the foundation for an upcoming Biologics License Application submission to the U.S. Food and Drug Administratio
Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
05.10.2026 11:15
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that could reshape the obesity drug race.
Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.
02.10.2026 08:23
Pfizer has been going through a period of transition.
How Much Do You Need Invested to Collect $8,450 a Month for Life?
01.10.2026 17:21
Turning a monthly paycheck into permanent investment income sounds straightforward until you realize how dramatically the required capital swings based on one variable most people overlook when building their retirement portfolio.
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
01.10.2026 06:30
NEW YORK, October 01, 2026--Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo. The findings were shared today in
Pfizer (PFE) Heads To ESMO With 45 Oncology Abstracts And Fresh Cancer Data
28.09.2026 14:09
Pfizer (NYSE:PFE) is set to feature data from 45 oncology research abstracts at the upcoming ESMO Congress. The company plans multiple oral presentations on late-stage cancer candidates alongside results for established oncology medicines. New clinical readouts at ESMO will spotlight Pfizer's late-stage oncology pipeline and marketed cancer drugs, against a broader backdrop our research has surfaced. Take a look at 4 warning signs we have identified for Pfizer. For investors tracking how...
BioNTech to Close Manufacturing Sites in Germany and Singapore After Sale Process Ends
28.09.2026 14:06
BioNTech (NASDAQ:BNTX) said on Monday that it will close manufacturing facilities in Germany and Singapore after a sales process for the sites did not result in completed transactions. The German vaccine maker had announced in May that it would seek buyers for facilities in Idar-Oberstein, Marburg and Tuebingen in Germany, as well as its Singapore site, with closures planned if purchasers could not be found.
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
28.09.2026 13:02
AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.
What Bavarian Nordic’s next CEO is up against
28.09.2026 12:50
The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform
28.09.2026 12:04
Alnylam Pharmaceuticals, Inc. is down on ATTR-CM fears. TRITON-CM could still succeed, downside is buffered, and shares look undervalued. Click for an ALNY update.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
28.09.2026 12:00
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
28.09.2026 10:45
NEW YORK, September 28, 2026--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer.